Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MF/F MDI 100 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MF | DEVICE | One evening dose of dry powder inhaled MF 400 μg (Multidose device). |
Inclusion Criteria: * Must be \>=18 years of age, of either gender \& of any race. * Must have had a diagnosis of asthma for at least 6 months, characterized by recurrent episode of wheezing, breathlessness, chest tightness \& coughing. * Baseline FEV1 must be \>=55% and \<=85% of predicted at the ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MF/F MDI 100 is an investigational inhaled therapy being studied for the treatment of asthma in adults. It is delivered as a metered dose inhaler and was evaluated in a Phase 3 clinical trial in patients with asthma. It is not described as approved for any use.
MF/F MDI 100 is being developed by Organon & Co., which trades under the ticker OGN. Organon is the sponsor of the clinical program evaluating this inhaled asthma therapy.
MF/F MDI 100 is in Phase 3 development. Its single registered trial, NCT00817817, is listed as a Phase 3 study and has completed. The drug remains investigational and is not described as FDA approved.
MF/F MDI 100 has been studied in one registered trial, NCT00817817, titled a study to determine the efficacy and safety of two mometasone dry powder inhalers in the treatment of asthma. That Phase 3 trial is completed, enrolled 93 participants, and included adults aged 18 years and older.
The Phase 3 trial NCT00817817 was a controlled study of MF/F MDI 100 in asthma, with 93 participants randomized. It was not double blind, enrolled adults 18 years and older of any sex, and did not use biomarker-based patient selection. The study is completed.